Pfizer
Bo Huang, PhD, FASA, is an experienced statistician currently serving as the Executive Director and head of the Non-Malignant Hematology Statistics Group at Pfizer since January 2008, managing over 15 statisticians in support of a portfolio that includes seven drugs in clinical development for hemophilia and sickle cell disease. Prior roles at Pfizer included Senior Director and Head of Immuno-Oncology Statistics, where Bo Huang led statistical initiatives for various cancers and drug submissions. Additional contributions to the field include serving as Associate Editor for journals such as the New England Journal of Statistics in Data Science and involvement with the American Statistical Association as Industry Co-Chair and Program Chair for the Biopharmaceutical Section. Educational foundations include a Ph.D. in Statistics from the University of Wisconsin-Madison and a B.S. in Mathematical Statistics from Nankai University.
Pfizer
605 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.